Latest News and Press Releases

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of...

Boston, Oct. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Anti-Parkinson's Drugs: Global Markets to 2030” is projected to grow from $6.1 billion in 2025 to $9.2...

Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin.

RetinalGenix Technologies and RGEN Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies

Therini Bio's novel approach to treating neurodegenerative diseases yielded positive results in a Phase 1a study evaluating its lead candidate, THN391.

Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients...

Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as...

Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as ChairFunding recognises Harness’...